Key Points NRx has launched commercial outreach for its U.S.-made, preservative-free ketamine, with initial supply agreements and preorders targeted for late 2026. Product shipments are…
November 11, 2026
November 09, 2026
Compass Pathways Takes COMP360 Psilocybin to FDA, Eyes 2027 Launch for Treatment-Resistant Depression
Key Points Compass Pathways completed its New Drug Application submission for COMP360 psilocybin in treatment-resistant depression. The application draws on two Phase 3 trials and…
Key Points EB-003 altered brain-wave activity in prefrontal and parietal cortical regions in mice, supporting functional activity in the central nervous system. Its profile differed…
November 02, 2026
Compass Pathways and DBSA Survey Highlights Burden of Treatment-Resistant Depression
Key Points A national survey included 261 people living with treatment-resistant depression and 73 caregivers. Some 95% of surveyed patients described themselves as functioning but…
October 21, 2026
Psyence BioMed Completes $2.6 Million PsyLabs Investment as Ibogaine Program Advances
Key Points Psyence BioMed invested an additional $2.6 million in PsyLabs after two development milestones were met. PsyLabs completed a regulatory preparation package, while Psyence’s…
Key Points NRx Pharmaceuticals completed three commercial-scale validation lots of its preservative-free ketamine. Two-year room-temperature testing showed no deterioration in purity, potency or sterility, according…
October 14, 2026
Compass Pathways Teams Up With Mental Health Groups to Raise Awareness of Treatment-Resistant Depression
Key Points Compass Pathways announced the first-ever U.S. Treatment-Resistant Depression Awareness Day, with support from NAMI, Mental Health America and the Depression and Bipolar Support…
October 07, 2026
Clearmind Urges FDA to Consider At-Home Pathways for Non-Hallucinogenic Psychedelic Therapies
Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biopharmaceutical company developing non-hallucinogenic, psychedelic-derived neuroplastogens, announced on October 7, 2026 that it submitted recommendations to the U.S….
Key Points Psyence BioMed’s Texas subsidiary, TIRC, signed a manufacturing agreement with Benuvia Operations for planned U.S. production of pharmaceutical-grade ibogaine API. Benuvia operates an…
Key Points TIRC and PsyLabs aim to sign a definitive agreement by November 30, 2026. If they do not, the binding term sheet will lapse….
September 17, 2026
Clearmind Medicine Presents Non-Hallucinogenic Psychedelic Research at FDA Hearing
Key Points Clearmind Medicine’s Chief of Global Impact, Mary-Elizabeth Gifford, testified at the FDA’s September 14 hearing on the potential future therapeutic use of psychedelic…
Key Points Definium Therapeutics said its Phase 3 Panorama trial met its main goal and all key secondary efficacy endpoints in adults with generalized anxiety…